Device Trial Radar · NCT04953949
IEIK13 For Neurosurgery
Last checked: Nov 20, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Aug 6, 2021
Primary completion
Aug 4, 2023
Study completion Nov 4, 2023
Sponsor
- Lead sponsor
- 3-D Matrix Europe SASNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 8, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical investigation is to determine the performance and safety profile of NU-MAX® when used as a topical hemostat for oozing bleedings encountered during intracranial procedures, in which control of bleeding by conventional hemostatic techniques is either ineffective or impractical.
Conditions
- Oozing (Hemorrhage) During Intracranial Procedures
Interventions
NU-MAX®Device
Topical Hemostat
Primary outcomes
What the sponsor says the trial is designed to measure.
- % of bleedings reaching hemostasis within 3 minutesTime frame: Intraoperatively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Antwerp University Hospital (UZA)
Edegem, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.